Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Current Liabilities (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Total Current Liabilities for 4 consecutive years, with $85.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 19.76% to $85.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85.8 million through Dec 2025, down 19.76% year-over-year, with the annual reading at $85.8 million for FY2025, 19.76% down from the prior year.
  • Total Current Liabilities hit $85.8 million in Q4 2025 for NewAmsterdam Pharma, up from $58.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $106.9 million in Q4 2024 to a low of $36.2 million in Q4 2022.
  • Historically, Total Current Liabilities has averaged $56.1 million across 4 years, with a median of $47.6 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: soared 114.28% in 2024 and later plummeted 31.5% in 2025.
  • Year by year, Total Current Liabilities stood at $36.2 million in 2022, then soared by 37.92% to $49.9 million in 2023, then skyrocketed by 114.28% to $106.9 million in 2024, then dropped by 19.76% to $85.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for NAMS at $85.8 million in Q4 2025, $58.3 million in Q3 2025, and $36.5 million in Q2 2025.